Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Consumer Reports of "Keto Flu" Associated With the Ketogenic Diet.

Bostock ECS, Kirkby KC, Taylor BV, Hawrelak JA.

Front Nutr. 2020 Mar 13;7:20. doi: 10.3389/fnut.2020.00020. eCollection 2020.

2.

The clinical profile of NMOSD in Australia and New Zealand.

Bukhari W, Clarke L, O'Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA.

J Neurol. 2020 Jan 31. doi: 10.1007/s00415-020-09716-4. [Epub ahead of print]

PMID:
32006158
3.

Validation of 0-10 MS symptom scores in the Australian multiple sclerosis longitudinal study.

Zhang Y, Taylor BV, Simpson S Jr, Blizzard L, Palmer AJ, van der Mei I.

Mult Scler Relat Disord. 2019 Dec 18;39:101895. doi: 10.1016/j.msard.2019.101895. [Epub ahead of print]

PMID:
31884383
4.

Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.

Zhou Y, Claflin SB, Stankovich J, van der Mei I, Simpson S Jr, Roxburgh RH, Kalincik T, Blizzard L, Lugaresi A, Alroughani R, Sajedi SA, Butzkueven H, Pucci E, Spitaleri D, Granella F, Cristiano E, Yamout B, Hughes S, Gouider R, Sánchez Menoyo JL, Olascoaga J, McGuigan C, Shaw C, Kermode AG, Kasa K, Al-Harbi T, Altintas A, Laureys G, Fragoso Y, Hardy TA, Csepany T, Sirbu CA, Decoo D, Sas A, Alvarez-Cermeño JC, Kotkata K, Millán-Pascual J, Taylor BV.

Mult Scler. 2019 Oct 31:1352458519881994. doi: 10.1177/1352458519881994. [Epub ahead of print]

PMID:
31668127
5.

Multifocal motor neuropathy: controversies and priorities.

Yeh WZ, Dyck PJ, van den Berg LH, Kiernan MC, Taylor BV.

J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):140-148. doi: 10.1136/jnnp-2019-321532. Epub 2019 Sep 11. Review.

PMID:
31511307
6.

The long-term effects of disease modifying therapies on disability in people living with multiple sclerosis: A systematic review and meta-analysis.

Claflin SB, Tan B, Taylor BV.

Mult Scler Relat Disord. 2019 Nov;36:101374. doi: 10.1016/j.msard.2019.08.016. Epub 2019 Aug 15. Review.

PMID:
31450158
7.

Change in multiple sclerosis prevalence over time in Australia 2010-2017 utilising disease-modifying therapy prescription data.

Campbell JA, Simpson S Jr, Ahmad H, Taylor BV, van der Mei I, Palmer AJ.

Mult Scler. 2019 Jul 26:1352458519861270. doi: 10.1177/1352458519861270. [Epub ahead of print]

PMID:
31347952
8.

Latitude continues to be significantly associated with the prevalence of multiple sclerosis: an updated meta-analysis.

Simpson S Jr, Wang W, Otahal P, Blizzard L, van der Mei IAF, Taylor BV.

J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1193-1200. doi: 10.1136/jnnp-2018-320189. Epub 2019 Jun 19.

PMID:
31217172
9.

The Association Between Vitamin D and Multiple Sclerosis Risk: 1,25(OH)2D3 Induces Super-Enhancers Bound by VDR.

Lu M, McComish BJ, Burdon KP, Taylor BV, Körner H.

Front Immunol. 2019 Mar 19;10:488. doi: 10.3389/fimmu.2019.00488. eCollection 2019.

10.

Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis.

Suanprasert N, Taylor BV, Klein CJ, Roforth MM, Karam C, Keegan BM, Dyck PJB.

Mult Scler Relat Disord. 2019 May;30:284-290. doi: 10.1016/j.msard.2019.02.026. Epub 2019 Feb 27.

PMID:
30870805
11.

Modelling the impact of multiple sclerosis on life expectancy, quality-adjusted life years and total lifetime costs: Evidence from Australia.

Palmer AJ, van der Mei I, Taylor BV, Clarke PM, Simpson S Jr, Ahmad H.

Mult Scler. 2019 Feb 26:1352458519831213. doi: 10.1177/1352458519831213. [Epub ahead of print]

PMID:
30806569
12.

Lipid-related genetic polymorphisms significantly modulate the association between lipids and disability progression in multiple sclerosis.

Zhang Y, Zhou Y, van der Mei IAF, Simpson S, Ponsonby AL, Lucas RM, Tettey P, Charlesworth J, Kostner K, Taylor BV; Ausimmune/AusLong Investigators Group.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):636-641. doi: 10.1136/jnnp-2018-319870. Epub 2019 Feb 19.

PMID:
30782980
13.

The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses.

Claflin SB, Broadley S, Taylor BV.

Front Neurol. 2019 Jan 10;9:1150. doi: 10.3389/fneur.2018.01150. eCollection 2018.

14.

Estimation of annual probabilities of changing disability levels in Australians with relapsing-remitting multiple sclerosis.

Ahmad H, van der Mei I, Taylor BV, Lucas RM, Ponsonby AL, Lechner-Scott J, Dear K, Valery P, Clarke PM, Simpson S, Palmer AJ.

Mult Scler. 2019 Nov;25(13):1800-1808. doi: 10.1177/1352458518806103. Epub 2018 Oct 23.

PMID:
30351240
15.

Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process.

Zhang Y, Taylor BV, Simpson S Jr, Blizzard L, van der Mei I.

Eur J Neurol. 2019 Jan;26(1):155-161. doi: 10.1111/ene.13786. Epub 2018 Sep 24.

PMID:
30133059
16.

What is the actual prevalence of migraine?

Yeh WZ, Blizzard L, Taylor BV.

Brain Behav. 2018 Jun;8(6):e00950. doi: 10.1002/brb3.950. Epub 2018 May 2.

17.

Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset.

Tao C, Simpson S Jr, Taylor BV, Blizzard L, Lucas RM, Ponsonby AL, Broadley S; AusLong/Ausimmune Investigators Group, van der Mei I.

Front Neurol. 2018 Jun 8;9:418. doi: 10.3389/fneur.2018.00418. eCollection 2018.

18.

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.

Chen J, Taylor BV, Blizzard L, Simpson S Jr, Palmer AJ, van der Mei IAF.

J Neurol Neurosurg Psychiatry. 2018 Nov;89(11):1200-1207. doi: 10.1136/jnnp-2018-318228. Epub 2018 Jun 19.

PMID:
29921609
19.

Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?

Taylor BV.

J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1015. doi: 10.1136/jnnp-2018-318326. Epub 2018 May 15. No abstract available.

PMID:
29764926
20.

Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction?

Jokubaitis VG, Zhou Y, Butzkueven H, Taylor BV.

Curr Treat Options Neurol. 2018 Apr 24;20(6):18. doi: 10.1007/s11940-018-0505-6. Review.

PMID:
29687310
21.

Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis.

Lu M, Taylor BV, Körner H.

Front Immunol. 2018 Mar 12;9:477. doi: 10.3389/fimmu.2018.00477. eCollection 2018. Review.

22.

The multiple sclerosis risk allele within the AHI1 gene is associated with relapses in children and adults.

Graves JS, Barcellos LF, Simpson S, Belman A, Lin R, Taylor BV, Ponsonby AL, Dwyer T, Krupp L, Waubant E, van der Mei IAF.

Mult Scler Relat Disord. 2018 Jan;19:161-165. doi: 10.1016/j.msard.2017.10.008. Epub 2017 Oct 14.

23.

Composite ganglioside autoantibodies and immune treatment response in MMN and MADSAM.

Martinez-Thompson JM, Snyder MR, Ettore M, McKeon A, Pittock SJ, Roforth MM, Mandrekar J, Mauermann ML, Taylor BV, Dyck PJB, Windebank AJ, Klein CJ.

Muscle Nerve. 2018 Jun;57(6):1000-1005. doi: 10.1002/mus.26051. Epub 2018 Jan 26.

PMID:
29272035
24.

Common genetic variation within miR-146a predicts disease onset and relapse in multiple sclerosis.

Zhou Y, Chen M, Simpson S Jr, Lucas RM, Charlesworth JC, Blackburn N, van der Mei I, Ponsonby AL; Ausimmune/AUSLONG investigators group, Taylor BV.

Neurol Sci. 2018 Feb;39(2):297-304. doi: 10.1007/s10072-017-3177-1. Epub 2017 Nov 10.

PMID:
29127522
25.

A New Method for Targeted and Sustained Induction of Type 2 Diabetes in Rodents.

Premilovac D, Gasperini RJ, Sawyer S, West A, Keske MA, Taylor BV, Foa L.

Sci Rep. 2017 Oct 26;7(1):14158. doi: 10.1038/s41598-017-14114-4.

26.

Systematic Review of Cognitive Function in Euthymic Bipolar Disorder and Pre-Surgical Temporal Lobe Epilepsy.

Bostock ECS, Kirkby KC, Garry MI, Taylor BVM.

Front Psychiatry. 2017 Aug 9;8:133. doi: 10.3389/fpsyt.2017.00133. eCollection 2017. Review.

27.

Complementary and alternative treatments of multiple sclerosis: a review of the evidence from 2001 to 2016.

Claflin SB, van der Mei IAF, Taylor BV.

J Neurol Neurosurg Psychiatry. 2018 Jan;89(1):34-41. doi: 10.1136/jnnp-2016-314490. Epub 2017 Aug 2. Review.

PMID:
28768821
28.

Genetic variation in the gene LRP2 increases relapse risk in multiple sclerosis.

Zhou Y, Graves JS, Simpson S Jr, Charlesworth JC, Mei IV, Waubant E, Barcellos LF, Belman A, Krupp L, Lucas R, Ponsonby AL, Taylor BV; Ausimmmune/AusLong investigators group.

J Neurol Neurosurg Psychiatry. 2017 Oct;88(10):864-868. doi: 10.1136/jnnp-2017-315971. Epub 2017 Jul 24.

PMID:
28739605
29.

Incidence and prevalence of NMOSD in Australia and New Zealand.

Bukhari W, Prain KM, Waters P, Woodhall M, O'Gorman CM, Clarke L, Silvestrini RA, Bundell CS, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brown M, Brownlee WJ, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Killpatrick T, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonell R, Mason DF, McCombe PA, Pender MP, Pereira JA, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt JDE, Slee M, Taylor BV, Willoughby E, Wilson RJ, Vincent A, Broadley SA.

J Neurol Neurosurg Psychiatry. 2017 Aug;88(8):632-638. doi: 10.1136/jnnp-2016-314839. Epub 2017 May 26.

30.

Variation within MBP gene predicts disease course in multiple sclerosis.

Zhou Y, Simpson S Jr, Charlesworth JC, van der Mei I, Lucas RM, Ponsonby AL; AUSLONG Investigators Group, Taylor BV.

Brain Behav. 2017 Mar 9;7(4):e00670. doi: 10.1002/brb3.670. eCollection 2017 Apr.

31.

The Current Status of the Ketogenic Diet in Psychiatry.

Bostock EC, Kirkby KC, Taylor BV.

Front Psychiatry. 2017 Mar 20;8:43. doi: 10.3389/fpsyt.2017.00043. eCollection 2017. Review.

32.

Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.

Lim CK, Bilgin A, Lovejoy DB, Tan V, Bustamante S, Taylor BV, Bessede A, Brew BJ, Guillemin GJ.

Sci Rep. 2017 Feb 3;7:41473. doi: 10.1038/srep41473.

33.

Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.

Tao C, Simpson S Jr, Taylor BV, van der Mei I.

J Neurol Sci. 2017 Jan 15;372:239-249. doi: 10.1016/j.jns.2016.11.060. Epub 2016 Nov 24. Review.

PMID:
28017222
34.

Multiple Sclerosis impact on employment and income in New Zealand.

Pearson JF, Alla S, Clarke G, Mason DF, Anderson T, Richardson A, Miller DH, Sabel CE, Abernethy DA, Willoughby EW, Taylor BV.

Acta Neurol Scand. 2017 Sep;136(3):223-232. doi: 10.1111/ane.12714. Epub 2016 Nov 28.

PMID:
27891575
35.

Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.

Tao C, Simpson S Jr, van der Mei I, Blizzard L, Havrdova E, Horakova D, Shaygannejad V, Lugaresi A, Izquierdo G, Trojano M, Duquette P, Girard M, Grand'Maison F, Grammond P, Alroughani R, Terzi M, Oreja-Guevara C, Sajedi SA, Iuliano G, Sola P, Lechner-Scott J, Pesch VV, Pucci E, Bergamaschi R, Barnett M, Ramo C, Singhal B, LA Spitaleri D, Slee M, Verheul F, Fernández Bolaños R, Amato MP, Cristiano E, Granella F, Hodgkinson S, Fiol M, Gray O, McCombe P, Saladino ML, Sánchez Menoyo JL, Shuey N, Vucic S, Shaw C, Deri N, Arruda WO, Butzkueven H, Spelman T, Taylor BV; MSBase Study Group.

J Neurol Neurosurg Psychiatry. 2016 Dec;87(12):1343-1349. doi: 10.1136/jnnp-2016-314013. Epub 2016 Nov 3.

PMID:
27810919
36.

Non-Obese Diabetes and Its Associated Factors in an Underdeveloped Area of South China, Guangxi.

Tang Z, Fang Z, Huang W, Liu Z, Chen Y, Li Z, Zhu T, Wang Q, Simpson S, Taylor BV, Lin R.

Int J Environ Res Public Health. 2016 Sep 30;13(10). pii: E976.

37.

The impact of multiple sclerosis severity on health state utility values: Evidence from Australia.

Ahmad H, Taylor BV, van der Mei I, Colman S, O'Leary BA, Breslin M, Palmer AJ.

Mult Scler. 2017 Jul;23(8):1157-1166. doi: 10.1177/1352458516672014. Epub 2016 Oct 3. Erratum in: Mult Scler. 2016 Dec;22(14 ):NP13.

PMID:
27698247
38.

Stressful life events and the risk of initial central nervous system demyelination.

Saul A, Ponsonby AL, Lucas RM, Taylor BV, Simpson S Jr, Valery P, Dwyer T, Kilpatrick TJ, Pender MP, van der Mei IA.

Mult Scler. 2017 Jun;23(7):1000-1007. doi: 10.1177/1352458516667566. Epub 2016 Sep 6.

PMID:
27600112
39.

Role of genetic susceptibility variants in predicting clinical course in multiple sclerosis: a cohort study.

Pan G, Simpson S Jr, van der Mei I, Charlesworth JC, Lucas R, Ponsonby AL, Zhou Y, Wu F, Taylor BV.

J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1204-1211. doi: 10.1136/jnnp-2016-313722. Epub 2016 Aug 24.

PMID:
27559181
40.

Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies.

George MF, Briggs FB, Shao X, Gianfrancesco MA, Kockum I, Harbo HF, Celius EG, Bos SD, Hedström A, Shen L, Bernstein A, Alfredsson L, Hillert J, Olsson T, Patsopoulos NA, De Jager PL, Oturai AB, Søndergaard HB, Sellebjerg F, Sorensen PS, Gomez R, Caillier SJ, Cree BA, Oksenberg JR, Hauser SL, D'Alfonso S, Leone MA, Martinelli Boneschi F, Sorosina M, van der Mei I, Taylor BV, Zhou Y, Schaefer C, Barcellos LF.

Neurol Genet. 2016 Aug 4;2(4):e87. doi: 10.1212/NXG.0000000000000087. eCollection 2016 Aug.

41.

Synergetic and antagonistic effects of combined calcitriol and interferon-β treatment on cytokine production by stimulated PBMCs.

Simpson S Jr, Stewart N, van der Mei I, Blizzard L, Taylor BV.

J Neuroimmunol. 2016 Aug 15;297:148-55. doi: 10.1016/j.jneuroim.2016.05.020. Epub 2016 May 31.

PMID:
27397088
42.

Axonopathy in peripheral neuropathies: Mechanisms and therapeutic approaches for regeneration.

Landowski LM, Dyck PJ, Engelstad J, Taylor BV.

J Chem Neuroanat. 2016 Oct;76(Pt A):19-27. doi: 10.1016/j.jchemneu.2016.04.006. Epub 2016 May 2. Review.

PMID:
27151423
43.

Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study.

Mahurkar S, Moldovan M, Suppiah V, Sorosina M, Clarelli F, Liberatore G, Malhotra S, Montalban X, Antigüedad A, Krupa M, Jokubaitis VG, McKay FC, Gatt PN, Fabis-Pedrini MJ, Martinelli V, Comi G, Lechner-Scott J, Kermode AG, Slee M, Taylor BV, Vandenbroeck K, Comabella M, Boneschi FM; Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), King C.

Pharmacogenomics J. 2017 Jul;17(4):312-318. doi: 10.1038/tpj.2016.20. Epub 2016 Mar 22.

PMID:
27001119
44.

Modeling the course and outcomes of multiple sclerosis is statistical twaddle--Yes.

Taylor BV.

Mult Scler. 2016 Feb;22(2):140-2. doi: 10.1177/1352458515625809. No abstract available.

PMID:
26830393
45.

Genetic loci for Epstein-Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis.

Zhou Y, Zhu G, Charlesworth JC, Simpson S Jr, Rubicz R, Göring HH, Patsopoulos NA, Laverty C, Wu F, Henders A, Ellis JJ, van der Mei I, Montgomery GW, Blangero J, Curran JE, Johnson MP, Martin NG, Nyholt DR, Taylor BV; ANZgene consortium.

Mult Scler. 2016 Nov;22(13):1655-1664. Epub 2016 Jan 27.

PMID:
26819262
46.

Disability profile of multiple sclerosis in New Zealand.

Alla S, Pearson JF, Taylor BV, Miller DH, Clarke G, Richardson A, Willoughby E, Abernethy DA, Sabel CE, Mason DF.

J Clin Neurosci. 2016 Jun;28:97-101. doi: 10.1016/j.jocn.2015.09.020. Epub 2016 Jan 4.

PMID:
26765754
47.

Low-density Lipoprotein Receptor-related Proteins in a Novel Mechanism of Axon Guidance and Peripheral Nerve Regeneration.

Landowski LM, Pavez M, Brown LS, Gasperini R, Taylor BV, West AK, Foa L.

J Biol Chem. 2016 Jan 15;291(3):1092-102. doi: 10.1074/jbc.M115.668996. Epub 2015 Nov 23.

48.

An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand.

Alla S, Pearson JF, Taylor BV, Roxburgh R, Clarke G, Miller DH, Richardson A, Abernethy DA, Willoughby E, Sabel CE, Mason DF.

Mult Scler. 2016 Apr;22(5):705-7. doi: 10.1177/1352458515605909. Epub 2015 Oct 2. No abstract available.

PMID:
26432856
49.

A new era in the treatment of multiple sclerosis.

Broadley SA, Barnett MH, Boggild M, Brew BJ, Butzkueven H, Heard R, Hodgkinson S, Kermode AG, Lechner-Scott J, Macdonell RA, Marriott M, Mason DF, Parratt J, Reddel SW, Shaw CP, Slee M, Spies JM, Taylor BV, Carroll WM, Kilpatrick TJ, King J, McCombe PA, Pollard JD, Willoughby E.

Med J Aust. 2015 Aug 3;203(3):139-41, 141e.1. Review.

PMID:
26224184
50.

Population attributable fractions and joint effects of key risk factors for multiple sclerosis.

van der Mei I, Lucas RM, Taylor BV, Valery PC, Dwyer T, Kilpatrick TJ, Pender MP, Williams D, Chapman C, Otahal P, Ponsonby AL.

Mult Scler. 2016 Apr;22(4):461-9. doi: 10.1177/1352458515594040. Epub 2015 Jul 21.

PMID:
26199349

Supplemental Content

Loading ...
Support Center